Neurosense Therapeutics Ltd Corporate and Clinical Update Call Transcript
(technical difficulty) Working hard to take into account everything that that and expand previous findings and support the future success of prime. With recent FDA clearance of our study, we are fully committed to meeting our timelines. The second topic is the pre-NDS meeting with Health Canada. Following productive discussions with the agency.
I'm glad to share that we are now back on track and believe we can advance the submission for conditional approval in Canada with the new data that we have generated. The third topic is the proof of concept Phase 2 program in Alzheimer's disease. We have recently completed a database log of our proof of concept study which we just announced today, and we anticipate top-line results in the first quarter of 2026.
We look forward to assessing the data to better understand if we may be able to address unmet needs in Alzheimer's. And the last topic for today is the partnership discussions. We recognize the importance of providing our investors and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
